Vogenx (NASDAQ:VOGX – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01, Zacks reports.
Vogenx Stock Down 4.3%
VOGX stock traded down $0.78 during mid-day trading on Friday, reaching $17.45. The company had a trading volume of 66,333 shares, compared to its average volume of 147,027. The firm has a market capitalization of $259.22 million and a PE ratio of -249.29. Vogenx has a one year low of $12.95 and a one year high of $38.41. The business has a 50-day moving average price of $23.45.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on VOGX. WBB Securities started coverage on shares of Vogenx in a research note on Wednesday, September 2nd. They issued a “speculative buy” rating and a $42.00 target price on the stock. Zacks Research raised Vogenx to a “hold” rating in a report on Monday, September 28th. JonesTrading initiated coverage on Vogenx in a research note on Tuesday, September 1st. They set a “buy” rating and a $55.00 price objective on the stock. Finally, Wall Street Zen raised shares of Vogenx to a “hold” rating in a report on Saturday, August 22nd. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $48.50.
Get Our Latest Research Report on Vogenx
Vogenx Company Profile
Vogenx, Inc is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. The company has historically concentrated on small-molecule drug candidates intended to address conditions in which existing treatment options may be limited.
Vogenx’s lead development program has included VGX-1027, an investigational anti-inflammatory compound studied for its potential to regulate abnormal immune responses. Research involving the candidate has focused on diseases associated with inflammation and immune-system dysfunction, although its development status and commercial availability may change over time.
The company’s activities have primarily involved pharmaceutical research and development rather than the marketing of an established portfolio of products.
Read More
- Five stocks we like better than Vogenx
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Vogenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vogenx and related companies with MarketBeat.com's FREE daily email newsletter.
